: Aim: To investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). Patients & methods: A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value. Progression-free survival and overall survival were analyzed. Results: Patients with sodium levels ≥140 mEq/l had significantly longer median progression-free survival (4.1 vs 2 months; p < 0.01) and median overall survival (12 vs 7.3 months; p < 0.01) compared with those with lower levels. Conclusion: This study suggests that higher pretreatment serum sodium levels are associated with improved outcomes in mCRC patients receiving aflibercept and FOLFIRI, potentially serving as a prognostic marker to aid treatment management.
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI / Catalano, Martina; Lavacchi, Daniele; Giommoni, Elisa; Shabani, Sonia; Guidolin, Alessia; Brugia, Marco; Petrioli, Roberto; Ramello, Monica; Pillozzi, Serena; Antonuzzo, Lorenzo; Roviello, Giandomenico. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - ELETTRONICO. - 19:(2023), pp. 2537-2546. [10.2217/fon-2023-0610]
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI
Catalano, Martina;Lavacchi, Daniele;Giommoni, Elisa;Shabani, Sonia;Guidolin, Alessia;Brugia, Marco;Pillozzi, Serena;Antonuzzo, Lorenzo;Roviello, Giandomenico
2023
Abstract
: Aim: To investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). Patients & methods: A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value. Progression-free survival and overall survival were analyzed. Results: Patients with sodium levels ≥140 mEq/l had significantly longer median progression-free survival (4.1 vs 2 months; p < 0.01) and median overall survival (12 vs 7.3 months; p < 0.01) compared with those with lower levels. Conclusion: This study suggests that higher pretreatment serum sodium levels are associated with improved outcomes in mCRC patients receiving aflibercept and FOLFIRI, potentially serving as a prognostic marker to aid treatment management.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
